Smith Group Asset Management’s Filana Therapeutics FLNA Stock Holding History

Smith Group Asset Management’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-280	Closed	-$12K	–	346
2021 Q4	$12K	Hold	280	–	–	﹤0.01%	292
2021 Q3	$17K	Sell	280 -180	-39%	-$15K	﹤0.01%	261
2021 Q2	$39K	Hold	460	–	–	﹤0.01%	182
2021 Q1	$21K	Buy	+460	New	+$18.1K	﹤0.01%	203

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Smith Group Asset Management's FLNA Position: Q1 2022 in Review

Smith Group Asset Management sold out of Filana Therapeutics (FLNA) in Q1 2022, closing a stake of 280 shares — an estimated $12K sold.

Smith Group Asset Management first reported a position in FLNA in Q1 2021 and held it in 4 quarters. The position peaked at $39K in Q2 2021. 163 funds tracked by Wall St. Rank hold FLNA as of Q1 2022.

Smith Group Asset Management reported no remaining Filana Therapeutics position as of Q1 2022 after selling out during the quarter.
Smith Group Asset Management sold 280 Filana Therapeutics shares in Q1 2022, an estimated $12K.
Smith Group Asset Management first reported a position in Filana Therapeutics in Q1 2021 and held it in 4 quarters.
Smith Group Asset Management's Filana Therapeutics position peaked at $39K in Q2 2021.
163 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2022.

Based on Smith Group Asset Management's 13F filing for Q1 2022, filed 5 May 2022.